122 related articles for article (PubMed ID: 36480329)
1. Establishment and Characterization of Single and Triple-Agent Resistant Osteosarcoma Cell Lines.
Low K; Hills F; Roberts HC; Stordal B
Adv Biol (Weinh); 2023 Feb; 7(2):e2200194. PubMed ID: 36480329
[TBL] [Abstract][Full Text] [Related]
2. Intrinsic resistance to chemotherapeutic agents in murine osteosarcoma cells.
Takeshita H; Kusuzaki K; Ashihara T; Gebhardt MC; Mankin HJ; Hirasawa Y
J Bone Joint Surg Am; 2000 Jul; 82-A(7):963-9. PubMed ID: 10901311
[TBL] [Abstract][Full Text] [Related]
3. LncRNA NORAD targets miR-410-3p to regulate drug resistance sensitivity of osteosarcoma.
Xie X; Liu W; Duan Z; Li X; Zhang L; Yang G
Cell Mol Biol (Noisy-le-grand); 2020 Jun; 66(3):143-148. PubMed ID: 32538761
[TBL] [Abstract][Full Text] [Related]
4. Pioglitazone modulates doxorubicin resistance in a in vivo model of drug resistant osteosarcoma xenograft.
Natarajan A; Ramachandran B; Gopisetty G; Jayavelu S; Sundersingh S; Rajkumar T
Naunyn Schmiedebergs Arch Pharmacol; 2021 Feb; 394(2):361-371. PubMed ID: 33015747
[TBL] [Abstract][Full Text] [Related]
5. Establishment of new multidrug-resistant human osteosarcoma cell lines.
Oda Y; Matsumoto Y; Harimaya K; Iwamoto Y; Tsuneyoshi M
Oncol Rep; 2000; 7(4):859-66. PubMed ID: 10854558
[TBL] [Abstract][Full Text] [Related]
6. Patient-derived osteosarcoma cells are resistant to methotrexate.
Dos Santos Cavalcanti A; Meohas W; Ribeiro GO; de Sá Lopes AC; Gholamin S; Razavi M; Hanae Kasai Brunswick T; Avan A; Matheus Guimarães JA; Leite Duarte ME; Kahn SA
PLoS One; 2017; 12(9):e0184891. PubMed ID: 28934267
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of nuclear factor-κB by dehydroxymethylepoxyquinomicin induces schedule-dependent chemosensitivity to anticancer drugs and enhances chemoinduced apoptosis in osteosarcoma cells.
Castro-Gamero AM; Borges KS; da Silva Silveira V; Lira RC; de Paula Gomes Queiroz R; Valera FC; Scrideli CA; Umezawa K; Tone LG
Anticancer Drugs; 2012 Jul; 23(6):638-50. PubMed ID: 22382389
[TBL] [Abstract][Full Text] [Related]
8. Micrometastatic Drug Screening Platform Shows Heterogeneous Response to MAP Chemotherapy in Osteosarcoma Cell Lines.
Collier CD; Wirtz EC; Knafler GJ; Morris WZ; Getty PJ; Greenfield EM
Clin Orthop Relat Res; 2018 Jul; 476(7):1400-1411. PubMed ID: 29481344
[TBL] [Abstract][Full Text] [Related]
9. ABCG1 and Pgp identify drug resistant, self-renewing osteosarcoma cells.
Roundhill EA; Jabri S; Burchill SA
Cancer Lett; 2019 Jul; 453():142-157. PubMed ID: 30910588
[TBL] [Abstract][Full Text] [Related]
10. Experimental models for the study of drug resistance in osteosarcoma: P-glycoprotein-positive, murine osteosarcoma cell lines.
Takeshita H; Gebhardt MC; Springfield DS; Kusuzaki K; Mankin HJ
J Bone Joint Surg Am; 1996 Mar; 78(3):366-75. PubMed ID: 8613443
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin (CDDP) specifically induces apoptosis via sequential activation of caspase-8, -3 and -6 in osteosarcoma.
Seki K; Yoshikawa H; Shiiki K; Hamada Y; Akamatsu N; Tasaka K
Cancer Chemother Pharmacol; 2000; 45(3):199-206. PubMed ID: 10663637
[TBL] [Abstract][Full Text] [Related]
12. Tranilast enhances the effect of anticancer agents in osteosarcoma.
Nakashima T; Nagano S; Setoguchi T; Sasaki H; Saitoh Y; Maeda S; Komiya S; Taniguchi N
Oncol Rep; 2019 Jul; 42(1):176-188. PubMed ID: 31059083
[TBL] [Abstract][Full Text] [Related]
13. Pioglitazone, an agonist of PPARγ, reverses doxorubicin-resistance in an osteosarcoma patient-derived orthotopic xenograft model by downregulating P-glycoprotein expression.
Higuchi T; Sugisawa N; Miyake K; Oshiro H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Kline Z; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
Biomed Pharmacother; 2019 Oct; 118():109356. PubMed ID: 31545293
[TBL] [Abstract][Full Text] [Related]
14. High energy shock waves enhance the cytotoxic effect of doxorubicin and methotrexate to human osteosarcoma cell lines.
Palmero A; Berger M; Venturi C; Ferrero I; Rustichelli D; Berta L; Frairia R; Madon E; Fagioli F
Oncol Rep; 2006 Jan; 15(1):267-73. PubMed ID: 16328067
[TBL] [Abstract][Full Text] [Related]
15. Reversion effects of curcumin on multidrug resistance of MNNG/HOS human osteosarcoma cells in vitro and in vivo through regulation of P-glycoprotein.
Si M; Zhao J; Li X; Tian JG; Li YG; Li JM
Chin Med J (Engl); 2013 Nov; 126(21):4116-23. PubMed ID: 24229684
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic virotherapy reverses chemoresistance in osteosarcoma by suppressing MDR1 expression.
Sugiu K; Tazawa H; Hasei J; Yamakawa Y; Omori T; Komatsubara T; Mochizuki Y; Kondo H; Osaki S; Fujiwara T; Yoshida A; Kunisada T; Ueda K; Urata Y; Kagawa S; Ozaki T; Fujiwara T
Cancer Chemother Pharmacol; 2021 Sep; 88(3):513-524. PubMed ID: 34114067
[TBL] [Abstract][Full Text] [Related]
17. Addressing Doxorubicin Resistance in Bone Sarcomas Using Novel Drug-Resistant Models.
Gallego B; Murillo D; Rey V; Huergo C; Estupiñán Ó; Rodríguez A; Tornín J; Rodríguez R
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742867
[TBL] [Abstract][Full Text] [Related]
18. 4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548): a promising new candidate for chemotherapeutic treatment of osteosarcoma patients.
Pasello M; Hattinger CM; Stoico G; Manara MC; Benini S; Geroni C; Mercuri M; Scotlandi K; Picci P; Serra M
Eur J Cancer; 2005 Sep; 41(14):2184-95. PubMed ID: 16140527
[TBL] [Abstract][Full Text] [Related]
19. Long Non-Coding RNA
Lee AM; Ferdjallah A; Moore E; Kim DC; Nath A; Greengard E; Huang RS
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681828
[TBL] [Abstract][Full Text] [Related]
20. Multiple pathways are involved in drug resistance to doxorubicin in an osteosarcoma cell line.
Rajkumar T; Yamuna M
Anticancer Drugs; 2008 Mar; 19(3):257-65. PubMed ID: 18510171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
